Figure 1.

Treatment response at a median follow-up of 3 months and 9 months after RTX treatment compared with baseline (BL). Changes in BVAS (A), daily prednisone dose (B), eosinophils (C), CRP concentrations (D), B-lymphocyte percentages (E), and IgE concentrations (F) are depicted. ***P < 0.001, **P < 0.01; *P < 0.05.

Thiel et al. Arthritis Research & Therapy 2013 15:R133   doi:10.1186/ar4313
Download authors' original image